药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Evinacumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Evinacumab.
Tiludronic acid
Sofituzumab vedotin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sofituzumab vedotin.
Tiludronic acid
Valanafusp alfa
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Valanafusp alfa.
Tiludronic acid
Gedivumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Gedivumab.
Tiludronic acid
Bleselumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bleselumab.
Tiludronic acid
Nemolizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Nemolizumab.
Tiludronic acid
Mitazalimab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mitazalimab.
Tiludronic acid
Suvratoxumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Suvratoxumab.
Tiludronic acid
Asunercept
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Asunercept.
Tiludronic acid
Ponezumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ponezumab.
Tiludronic acid
Zolbetuximab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Zolbetuximab.
Tiludronic acid
Utomilumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Utomilumab.
Tiludronic acid
Telisotuzumab vedotin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Telisotuzumab vedotin.
Tiludronic acid
Tigatuzumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tigatuzumab.
Tiludronic acid
Tezepelumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tezepelumab.
Tiludronic acid
Frovocimab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Frovocimab.
Tiludronic acid
Abrilumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Abrilumab.
Tiludronic acid
Ipafricept
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ipafricept.
Tiludronic acid
Tafasitamab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tafasitamab.
Tiludronic acid
Apomab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Apomab.